We find that in vitro, loss of IFNγR signaling promotes potent B-ALL tumor cell resistance to CAR-T killing while in vivo loss results in sensitivity. This evidence concerns the gene IFNGR1 and precursor B-cell acute lymphoblastic leukemia.